Article
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Nature communications - 15 Jul 2022
Bardia Aditya, Chandarlapaty Sarat, Linden Hannah M, Ulaner Gary A, Gosselin Alice, Cartot-Cotton Sylvaine, Cohen Patrick, Doroumian Séverine, Paux Gautier, Celanovic Marina, Pelekanou Vasiliki, Ming Jeffrey E, Ternès Nils, Bouaboula Monsif, Lee Joon Sang, Bauchet Anne-Laure, Campone Mario
Abstract excerpt
AMEERA-1 is a Phase 1/2 open-label single-arm study evaluating once-daily (QD) amcenestrant, an orally bioavailable selective estrogen receptor (ER) degrader, in postmenopausal women with ER+/HER2- advanced breast cancer (NCT03284957), who were mostly heavily pretreated (including targeted therapies and fulvestrant). In the dose escalation phase (Part A: n = 16), patients received amcenestrant 20-600 mg QD. Based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.